Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder that affects the cilia, the microscopic, hair-like structures that line the airways, ears, and other parts of the body. These cilia play a crucial role in moving mucus and other substances out of the respiratory tract and other areas. When cilia do not function properly due to genetic mutations, it can lead to a variety of health issues, including chronic respiratory infections, sinusitis, and issues with fertility. One of the genes associated with PCD is the CCNO gene, and mutations in this gene can lead to a specific subtype of the condition known as Primary Ciliary Dyskinesia Type 29.
Symptoms of CCNO Gene Primary Ciliary Dyskinesia Type 29 can vary widely among individuals but typically include chronic respiratory infections starting from a young age, persistent cough, sinusitis, and middle ear infections. In some cases, individuals may also experience situs inversus, a condition where the major visceral organs are reversed or mirrored from their normal positions. Understanding the symptoms is crucial for early diagnosis and management of the condition.
Diagnosing Primary Ciliary Dyskinesia, especially its specific types like CCNO-related PCD, relies heavily on genetic testing. This is where DNA Labs UAE comes into play, offering a specialized CCNO Gene Primary Ciliary Dyskinesia Type 29 Genetic Test. This test is designed to detect mutations in the CCNO gene, providing vital information for accurate diagnosis and management of the condition.
The cost of the CCNO Gene Primary Ciliary Dyskinesia Type 29 Genetic Test at DNA Labs UAE is 4400 AED. While the price may seem significant, the value of a precise diagnosis cannot be understated. It opens the door for targeted treatments and interventions, potentially improving the quality of life for those affected by the condition.
- Chronic respiratory infections
- Persistent cough
- Sinusitis
- Middle ear infections
- Potential for situs inversus
Understanding the symptoms and genetic underpinnings of Primary Ciliary Dyskinesia Type 29 is the first step towards effective management. With advancements in genetic testing, such as the services offered by DNA Labs UAE, individuals and families affected by this condition can access the information needed for a better health outcome. The CCNO Gene Primary Ciliary Dyskinesia Type 29 Genetic Test is a pivotal resource in this journey, offering hope and direction for those navigating the complexities of this genetic disorder.
